Guest Blog|Incentivising innovation in life sciences requires a fresh debate

New incentives should be explored to encourage innovation in life sciences, especially in areas where the traditional model of incentives might not be working or sufficiently encouraging the development of medicines that society needs.

HotHouse BioEngineering and Leaf Expression Systems Sign Plant-Based Expression License Agreement

NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.

R&D Tax Credits – The three most common areas life sciences companies underclaim

We all know how important R&D tax credits are for the Life Sciences, Pharmaceuticals, and Biotech sectors. Most companies in these industries have been claiming since day one, and yet we often encounter companies who are significantly underclaiming. The average benefit for companies in these industries is just over £110k, but Ayming’s average claim for companies in these industries is currently more than £700k, so why is there such a discrepancy?

CEO Update | Monday 12 April

It was fantastic to see the launch of the Medicines & Diagnostics Manufacturing Transformation Fund which aims to boost economic opportunities, innovation and health resilience by supporting medicines and diagnostics manufacturing investments in the UK.

Cancer Research UK launches new ‘cancer tech accelerator’ programme

Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.

Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021

Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of MDX-124 - the company’s proprietary therapeutic antibody.

FairJourney Biologics enters next-generation antibody discovery collaboration with argenx

• Collaboration to leverage IONTAS proprietary mammalian display technology • Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology pipeline

The best in AI appointed at Norwich Research Park

Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.

Coulter Partners secures Chair of the Board for OxSonics Therapeutics

Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.

PrecisionLife unveils new spin-out Synomics taking its proven analytics platform into animal and crop health sectors

PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out Synomics Ltd. Synomics will develop and market applications of the PrecisionLife® combinatorial analytics platform for the improvement of the health and yield of livestock and crops in sustainable agriculture and food production. Wheatsheaf Group, PrecisionLife’s lead investor has invested in Synomics, with PrecisionLife retaining a minority equity holding.